For CCX282. Unless and until GSK exercises its Product Option with respect to CCX282 or a CCX282 Back-up Compound, promptly after the conduct of each of the following (a) the PROTECT-1 Induction Phase, (b) the PROTECT-1 Maintenance Phase,
Appears in 2 contracts
Sources: Product Development and Commercialization Agreement (ChemoCentryx, Inc.), Product Development and Commercialization Agreement (ChemoCentryx, Inc.)